» Articles » PMID: 36244871

Accommodation in Allogeneic and Xenogeneic Organ Transplantation: Prevalence, Impact, and Implications for Monitoring and for Therapeutics

Overview
Journal Hum Immunol
Date 2022 Oct 16
PMID 36244871
Authors
Affiliations
Soon will be listed here.
Abstract

Accommodation refers to acquired resistance of organs or tissues to immune or inflammatory reactions that might otherwise cause severe injury or rejection. As first observed in ABO-incompatible kidney transplants and heterotopic cardiac xenografts, accommodation was identified when organ transplants continued to function despite the presence of anti-graft antibodies and/or other reactants in the blood of recipients. Recent evidence suggests many and perhaps most organ transplants have accommodation, as most recipients mount B cell responses specific for the graft. Wide interest in the impact of graft-specific antibodies on the outcomes of transplants prompts questions about which mechanisms confer protection against such antibodies, how accommodation might be detected and whether and how rejection could be superimposed on accommodation. Xenotransplantation offers a unique opportunity to address these questions because immune responses to xenografts are easily detected and the pathogenic impact of immune responses is so severe. Xenotransplantation also provides a compelling need to apply these and other insights to decrease the intensity and toxicity of immunosuppression that otherwise could limit clinical application.

Citing Articles

Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies.

Galili U Front Mol Biosci. 2023; 10:1209974.

PMID: 37449060 PMC: 10338101. DOI: 10.3389/fmolb.2023.1209974.


Immune characterization of a xenogeneic human lung cross-circulation support system.

Wu W, Stier M, Stokes J, Ukita R, Patel Y, Cortelli M Sci Adv. 2023; 9(13):eade7647.

PMID: 37000867 PMC: 10065447. DOI: 10.1126/sciadv.ade7647.

References
1.
Cascalho M, Platt J . TNFRSF13B in B cell responses to organ transplantation. Hum Immunol. 2022; 84(1):27-33. PMC: 10429825. DOI: 10.1016/j.humimm.2022.09.006. View

2.
Platt J, Cascalho M, Piedrahita J . Xenotransplantation: Progress Along Paths Uncertain from Models to Application. ILAR J. 2018; 59(3):286-308. PMC: 6808066. DOI: 10.1093/ilar/ily015. View

3.
Fan X, Ang A, Pollock-Barziv S, Dipchand A, Ruiz P, Wilson G . Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med. 2004; 10(11):1227-33. DOI: 10.1038/nm1126. View

4.
Lin S, Hanaway M, Gonzalez-Stawinski G, Lau C, Parker W, Davis R . The role of anti-Galalpha1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation. 2001; 70(12):1667-74. DOI: 10.1097/00007890-200012270-00002. View

5.
van der Jagt R, Badger C, Appelbaum F, Press O, Matthews D, Eary J . Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 1992; 52(1):89-94. View